微粒化阴道黄体酮预防流产:随机证据的批判性评估
本文批判性评估了早期妊娠使用微粒化阴道黄体酮预防流产的随机证据。两项大型高质量安慰剂对照试验(PROMISE和PRISM)显示总体活产率提高约3%但统计不确定性大;
要点
- 总体人群获益不确定,但既往流产次数越多,活产率提升越明显
- 既往流产≥1次且本次妊娠出血者,黄体酮显著提高活产率
- 既往流产≥3次且本次出血者,活产率绝对提升15%(72% vs 57%)
核心结论
- 对于有流产史且本次早期妊娠出血的女性,阴道微粒化黄体酮400mg每日两次可能获益。
- 总体人群的获益具有统计不确定性,需结合既往流产次数和出血情况个体化决策。
研究设计与样本
- PROMISE试验:英国和荷兰45家医院836名不明原因复发性流产女性,安慰剂对照。
- PRISM试验:英国48家医院4153名早期妊娠出血女性,安慰剂对照。
主要发现
- PROMISE试验:黄体酮组活产率提高3%,但统计不确定性大。
- 两项试验均未发现短期安全性问题。
关键数值与推荐
- 阴道微粒化黄体酮用法:400mg每日两次。
- 亚组分析满足可信亚组分析的11项条件。
临床怎么用
- 对有流产史且早期妊娠出血的女性,可考虑使用阴道微粒化黄体酮400mg每日两次。
- 治疗决策应结合患者既往流产次数和当前出血情况,进行共享决策。
局限性
- 总体人群的获益未达到常规统计学显著性,PROMISE试验统计不确定性大。
- 亚组分析结果需谨慎解读,主要获益限于特定高风险亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone supplementation may reduce the risk of miscarriage in women with recurrent or threatened miscarriage. Cochrane Reviews summarized the evidence and found that the trials were small with substantial methodologic weaknesses. Since then, the effects of first-trimester use of vaginal micronized progesterone have been evaluated in 2 large, high-quality, multicenter placebo-controlled trials, one targeting women with unexplained recurrent miscarriages (the PROMISE [PROgesterone in recurrent MIScarriagE] trial) and the other targeting women with early pregnancy bleeding (the PRISM [PRogesterone In Spontaneous Miscarriage] trial). The PROMISE trial studied 836 women from 45 hospitals in the United Kingdom and the Netherlands and found a 3% greater live birth rate with progesterone but with substantial statistical uncertainty. The PRISM trial studied 4153 women from 48 hospitals in the United Kingdom and found a 3% greater live birth rate with progesterone, but with a P value of .08. A key finding, first observed in the PROMISE trial, and then replicated in the PRISM trial, was that treatment with vaginal micronized progesterone 400 mg twice daily was associated with increasing live birth rates according to the number of previous miscarriages. Prespecified PRISM trial subgroup analysis in women with the dual risk factors of previous miscarriage(s) and current pregnancy bleeding fulfilled all 11 conditions for credible subgroup analysis. For the subgroup of women with a history of 1 or more miscarriage(s) and current pregnancy bleeding, the live birth rate was 75% (689/914) with progesterone vs 70% (619/886) with placebo (rate difference 5%; risk ratio, 1.09, 95% confidence interval, 1.03-1.15; P=.003). The benefit was greater for the subgroup of women with 3 or more previous miscarriages and current pregnancy bleeding; live birth rate was 72% (98/137) with progesterone vs 57% (85/148) with placebo (rate difference 15%; risk ratio, 1.28, 95% confidence interval, 1.08-1.51; P=.004). No short-term safety concerns were identified from the PROMISE and PRISM trials. Therefore, women with a history of miscarriage who present with bleeding in early pregnancy may benefit from the use of vaginal micronized progesterone 400 mg twice daily. Women and their care providers should use the findings for shared decision-making.
引用
- Coomarasamy A, Devall AJ, Brosens JJ, et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020. PMID: 32008730. doi:10.1016/j.ajog.2019.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。